William Robinson, MD


Professor of Gynecologic Oncology
Maxwell E Lapham
Director
Tulane Minority-Based Community Clinical
Oncology Program
Tulane University School of Medicine
New Orleans, LA, USA

Biography

Dr. Robinson is currently the Maxwell E Lapham Professor of Gynecologic Oncology at Tulane University School of Medicine. He also serves as Principal Investigator and Director for Tulane’s Minority-Based Community Clinical Oncology Program, as well as Director of Tulane’s “Woman to Woman” Survivor Advocacy program and Medical Director of Grace House, a New Orleans-based inpatient Substance Abuse Rehab Center for Women.
Dr Robinson completed Residency training in Obstetrics and Gynecology at Tulane University School of Medicine/New Orleans in 1989, and Fellowship in Gynecologic Oncology at the University of Southern California/LA County in 1992. He has worked in both academic and private practice positions since then, with a career-long commitment to serving indigent and ethnic minority women. In particular, he has worked hard to create opportunities for those women to participate in cancer prevention and treatment research, which has traditionally failed to include representative numbers of ethnic minorities.
He sits on the Cancer Prevention and Control committee and Health Disparities committee of the NRG Cooperative group cancer research program, the Health Economics and Coding Committee of the American Congress of Obstetrics and Gynecology, and is Chairman of the Coding Committee of the Society of Gynecologic Oncology.
Currently he is working to build a Cancer Research and Prevention program in inner city New Orleans, with emphasis on 1) Prevention of cancer in this community; and 2) reducing the barriers to participation in clinical research that exist among local indigent and ethnic minority residents.

Research Interest

His research interests include: HIV infection and cancer in women, intraperitoneal chemo- and immunotherapy for ovarian cancer, Survivorship research, and Coding, Nomenclature and Economics of cancer.

Scientific Activities

MEMBERSHIPS:

• American College/Congress of Obstetricians and Gynecologists Junior Fellow-1987 Fellow – 1993 to Present
• Health Economics and Coding Committee-2013- Present
• Western Association of Gynecologic Oncology-1994- Present
• American Society of Clinical Oncology- 1994 – Present
• Society of Gynecologic Oncologists/Oncology Fellow – 1996 – Present
• Foundation for Women’s Cancer (formerly Gynecologic Cancer Foundation) Member-1995-present
• Liaison, N.E.D. (No Evidence of Disease) -2009- Present
• Society of Critical Care Medicine -1994 – Present

ADMINISTRATIVE FUNCTIONS:
• Northwest Texas Hospital Pharmacy and Therapeutics Committee – 2000- Present
• Northwest Texas Hospital Cancer Committee 2001-Present
• Texas Medical Board, Case Reviewer- 2005- Present

Publications

Peer-Reviewed Publications:

1. Dixit SN, Robinson W, Dixit P, Kang A. Immunochemistry of 7s Domain of Type IV Collagen. Connective Tissue Research. 1984; Vol. 12: 297-306.
2. RobinsonW, DeShazo R. Effects of HIV infection on pregnancy. A clinical and immunologic evaluation. Annals of Allergy. 1991;Vol. 676: 350-354.
3. Zheng J, Robinson W, Ehlen TE, Yu M, Dubeau L. Distinction of low grade from high-grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3,6 and 11 and HER-2/neu gene amplification. Cancer Research. 1991; Vol. 51(14): 4045-4051.
4. Robinson W, Curtin JP, Morrow CP. Operative staging and conservative surgery in the management of low malignant potential ovarian tumors. Inter J Gynecol Cancer. 1992; Vol.2: 113-118. doi: 10.1046/j.1525-1438.1992.02030113.x
5. Robinson W, Muderspach LI. Spinal cord compression in metastic cervical cancer. Gyn. Oncol. 1993; 48: 209-271. doi: http://dx.doi.org/10.1006/gyno.1993.1046
6. Robinson W. Management of ovarian tumors of low malignant potential. The Female Patient. 1994; 19: 45-58.
7. Robinson W, Fleischer M. Prenatal human immunodeficiency virus testing and patient management by obstetricians in a high seroprevalence community. Infect Dis Obstet Gynecol. 1994; 2: 25-29. doi: 10.1155/S1064744994000359
8. Devito JR, Robinson W. Gynecological surgical outcomes among asymptomatic human immunodeficiency virus-infected women and uninfected control subjects. J Louis St Med Soc. 1995; 147: 109-112.
9. Robinson W, Wiley D, Van Dyke R. The effect of successive single gestation pregnancies on the course of maternal HIV disease and perinatal transmission. Infect Dis Obstet Gynecol. 1995; 2: 251-254. doi: 10.1155/S1064744995000135
10. Freeman SM, McCune C, Robinson W, et al. The treatment of ovarian cancer with a gene-modified cancer vaccine: A Phase I Study. Human Gene Therapy. 6: 927-939, 1995. doi: 10.1089/hum.1995.6.7-927.
11. Simmons B, Robinson W, Meleg-Smith S. An 81-year-old woman with an abdominal mass. J La State Med Soc. 1995; 147: 512-515.
12. Freeman SM, Marrogi AJ, Ramesh R, Robinson W. Suicide Gene Therapy for the treatment of ovarian cancer. Cancer Detection and Prevention. 19: 111-112, 1995.
13. Robinson W, Tirpack J. The predictive value of LEEP specimens with involved margins for residual dysplasia. Int J Gynecol Oncol. 1996; 6: 140-144. doi: 10.1046/j.1525-1438.1996.06020140.x
14. Robinson W, Champlin S. A trial of secondary closure vs second intention closure in surgical wound separation. J Gynecol Tech. 2: 13-18, 1996.
15. Hamilton C, Robinson W. Femoral artery occlusion following pelvic cancer surgery. Gynecol Oncol. 1996; 63: 151-153. doi: http://dx.doi.org/10.1006/gyno.1996.0296
16. Merogi AJ, Marrogi AJ, Ramesh R, Robinson W, Fermin CD, Freeman SM. Tumor-host interaction: analysis of cytokines, growth factors and tumor infiltrating lymphocytes in ovarian carcinomas. Human Pathol. 1997; 28: 321-331. doi: 10.1016/S0046-8177(97)90131-3
17. Robinson W, Webb S, Tirpack S, Degefu S, OGuinn AG. Management of cervical intraepithelial neoplasia during pregnancy with LOOP excision. Gynecol Oncol. 1997; 64: 153-155. doi: 10.1006/gyno.1996.4546
18. Robinson W, Roberts A, Halabi S, Adams J. Risk Factors for margin involvement in specimens generated by LEEP excision of the cervix. J Gynecol Tech. 1997; 3: 17-20.
19. Robinson W, Barnes S, Adams S, Perrin M. Histology/Cytology discrepancies in HIV-infected obstetric patients with normal pap smears. Gynecol Oncol. 1997; 65: 430433. doi: 10.1006/gyno.1997.4683
20. Robinson W, Lund ED, Adams J. The predictive value of LEEP specimen margin status for residual/recurrent cervical intraepithelial neoplasia. Int J Gyncol Oncol. 8: 109-112, 1998. doi: 10.1046/j.1525-1438.1998.97112.x
21. Robinson W, Adams J, OQuinn AG, Freeman S. Vaccine therapy for ovarian cancer using Herpes Simplex Virus Thymidine Kinase (HSV-TK) suicide gene transfer technique: A Phase I Trial. Gene Ther Molec Biol. 1998; 2: 31-40.
22. Kahan Z, Arencibia J, Csernus V, et al. Expression of growth hormone releasing-hormone (GHRH) mRNA and the presence of biologically active GHRH in human breast, endometrial and ovarian cancers. J Clinical Endocrin and Metabo. 1999; 84(2): 582-589. doi: 10.1210/jc.84.2.582
23. Robinson WR, Mamdoohin N, Adams J, Kline R. Technical Aspects Intraperitoneal Adminstration of a Gene-Modifed Ovarian Cancer Vaccine. J Gynecol Tech. 1999; 5: 79-82.
24. Lin WM, Michalapulos EA, Dhurandar N, et al. Allelic loss and microsatellite alterations of chromosome 3p14.2 are more frequent in recurrent cervical dysplasias. Clin Canc Res. 2000; 6: 1410-1414.
25. Lavey RS, Liu PY, Greer BE, et al. Recombinant human eryghropoietin (EPO) as an adjunct to radiation therapy (RT) and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study. Radiother Oncol. 2000; 56(suppl 1): A-330, S92.
26. Robinson W, Hamilton CA, Micheals SH, Kissinger P. The effects of excisional therapy and highly active antiretroviral therapy on cervical intraepithelial neoplasia in human immunodeficiency virus-infected women. Am J Obstet Gynecol. 2001; 184(4): 538-43. doi: http://dx.doi.org/10.1067/mob.2001.111103
27. Robinson W, Freeman D. Improved outcome of cervical neoplasia in HIV-infected women in the highly active antiretroviral therapy (HAART) era. AIDS Patient Care and STDs. 2002; 16(2): 61-65. doi: 10.1089/10872910252806108
28. Robinson W, Luck M, Morris K, Pruitt B. Gender differences in hospice utilization by cancer patients in an end-of-life transition program. JAMWA. 2002; 57(2): 1-3.
29. Robinson W, Andersen J, Darragh T, Kendall M, Clark R, Maiman M. Isotretinoin for low grade cervical dysplasia in human immunodeficiency virus-infected women. Obstet Gynecol. 2002; 99(5): 777-784. doi: 10.1016/S0029-7844(02)01949-X
30. Clark R, Kendall M, Robinson W. Progression of cervical disease among adolescents infected with human immunodeficiency virus with low grade squamous intraepithelial lesions. JAIDS. 2002; 31(5): 543-545.
31. Robinson W, Luck M, Kendall M, Darraugh T. The predictive value of cytology in HIV-infected women with low grade squamous cervical lesions: A sub-study of a randomized, Phase III chemoprevention trial. Am J Obstet Gynecol. 2003; 188(4): 896-900. doi: 10.1067/mob.2003.205
32. Nouriani M, Bahador A, Berek JS, et al. Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy. Clin Cancer Res. 2004; 10(8): 2681-6. doi: 10.1158/1078-0432.CCR-0523-03
33. Lavey RS, Liu PY, Greer BE, et al. Recombinant human erythropoietin (EPO) as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group Study. Gynecol Oncol. 2004; 95: 145-151. doi: http://dx.doi.org/10.1016/j.ygyno.2004.07.009
34. Robinson WR, Omar H, Blades N. Toxicity of Intraperitoneal Chemotherapy may be related to Age in Women Treated for Optimally Debulked Ovarian Cancer. Commun Oncol. 2005; 2: 271-275.
35. Luck MB, McIntire M, Blades N, Robinson WR. Characteristics of Women with Gynecologic Cancers who enter Clinical Trials. J Reprod Med. 2005; 50: 481-485.
36. Robinson WR, Luck M, Omar H, Blades N, Morris K, Coscia J. A Pilot Study of Bone Density Loss in Menopausal Women Treated with Chemotherapy for Cancer. Support Care Cancer. 2005; 13(8): 663-667. doi: 10.1007/s00520-005-0798-3
37. Dadabayev AR, Wang Z, Zhang Y, Zhang J, Robinson WR, Lim SH. Cancer Immunotherapy Targeting Sp17: When should the Laboratory Findings Be Translated to the Clinics? Am J Hemat. 2005; 80: 6-11. doi: 10.1002/ajh.20415
38. Smith HO, Jiang C, Weiss GR, et al. Tiripazamine plus Cisplatinum in Advanced or Recurrent Carcinoma of the Uterine Cervix: A Southwest Oncology Group Study. Int J Gynecol Cancer. 2006; 16(1): 298-305.
39. English CA, Pruitt P, Robinson WR. Detecting Asymptomatic Endometrial Carcinoma by Combined PET/CT. Commun Oncol. 2006; 3: 246,255. doi: 10.1016/S1548-5315(11)70692-1
40. Robinson WR, Cunningham AJ, Rogers AS. Deep Vein Thrombosis Management in Women with Cancer. Support Palliat Canc Care. 2006; 3(1): 1-4.
41. Robinson WR. What Would You Do? Gynecol Oncol. 2007; 104: 5-7.
42. English CA, Robinson WR. Primary adenocarcinoma of the sigmoid colon diagnosed by uterine curettage: a case report. Commun Oncol. 2007; 4(3): 402-403. doi: 10.1016/S1548-5315(11)70147-4
43. Wright SE, Rewers-Felkins KA, Quinlin IS, et al. MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells. Immun Invest. 2008; 37: 215-225. doi: 10.1080/08820130801967874.
44. Robinson WR, Barnett G, Rogers AS. Neoadjuvant chemotherapy prior to intraperitoneal chemotherapy in women with advanced ovarian cancer. Commun Oncol. 2008; 5(7): 376-380.
45. Robinson WR, Davis N, Rogers AS. Paclitaxel maintenance chemotherapy following intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2008; 18(5): 891-895. doi: 10.1111/j.1525-1438.2007.01118.x
46. Robinson WR, Coberly C, Beyer J, Lewis A, Ballard K. Office-Based Intraperitoneal Chemotherapy for Ovarian Cancer. J Oncol Practice. 2008; 4(5): 225-228. doi: 10.1200/JOP.0858503.
47. Robinson WR, Ritter J, Rogers A, Tedjarati S, Lieberenz C. Clinical Trial Participation is Associated with Improved Outcome in Women with Ovarian Cancer. Int J Gynecol Cancer. 2009; 19(1): 124-128. doi: 10.1111/IGJ.0b013e31819a1ce8
48. Tiersten A, Liu PY, Smith H, et al. Phase II Evaluation of Neoadjuvant Chemotherapy and Debulking Followed by Intraperitoneal Chemotherapy in Women with Stage III and IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer: Southwest Oncology Group Study S0009. Gynecol Oncol. 2009; 111(3): 444-449. doi: 10.1016/j.ygyno.2008.10.028.
49. Markman M, Smith Ho, Moon J, et al. Southwest Oncology Group Trial S9912: Inrtraperitoneal Cisplatin and Paclitaxel plus Intravenous Paclitaxel and Pegylated Liposomal Doxyrubicin as Primary Chemotherapy of Small-Volume Residual Stage III Ovarian Cancer. Gynecol Oncol. 2009; 114(2): 206-209. doi: 10.1016/j.ygyno.2009.04.023.
50. Robinson WR, Perry EK, Beyer J, Lieberenz C. Intraperitoneal Chemotherapy for Ovarian Cancer. Commun Oncol. 2010; 7(2): 1-6.
51. Robinson WR, Beyer J. Factors affecting the completion of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Oncol. 2010; 20(1): 70-74. doi: 10.1111/IGC.0b013e3181c7f670.
52. Tiersten A, Liu PY, Smith H, et al. Chemtherapy Resistance as a Predictor of Progression-Free Survival in Ovarian Cancer Patients treated with Neoadjuvant Chemotherapy and Surgical Cytoreduction Followed by Intraperitoneal Chemotherapy: A Southwest Oncology Group Study. Oncology. 2010; 77(6): 395-399.
53. Ballard KS, Tedjarati SS, Robinson WR, Homesley H, Thurston E. Embryonal Rhabdomyosarcoma: Adjuvant and Ex Vivo Assay Directed Chemotherapy. Int J Gynecol Cancer. 2010; 20(4): 561-563. doi: 10.1111/IGC.0b013e3181d320dd.
54. Robinson WR, Beyer J. The Impact of Shifting From Office-Based to Hospital-Based Treatment Facilities on the Administration of Intraperitoneal Chemotherapy for Ovarian Cancer. J Oncol Practice. 2010; 6(5): 232-235. doi: 10.1200/JOP.000058
55. Li, CC, Robinson WR, Rew L. Factors Affecting Sexual Function and Sexual Satisfaction among Females with or without Rectal Cancer or Gynecological Cancer. Univ Texas Dig Repos. 2011;
56. Robinson WR, Griffin S, Beyer J, Kanjanavaikoon P. Extraperitoneal Metastases from Recurrent Ovarian Cancer. Int J Gynecol Cancer. 2012; 22(1): 43-46. doi: 10.1097/IGC.0b013e31823532ce.
57. Dobranski MJ, Wright SE, Robinson WR, Felkins KA, Phillips CA. Immunotherapy With IL-10 and IFN-γ Producing CD4 Effector Cells Modulate Natural And Inducible CD4 TReg Cell Subpopulation Levels: Observations In Four Cases Of Patients With Ovarian Cancer. Cancer Immun Immunotherapy. 2012; 61(6): 839-854. doi: 10.1007/s00262-011-1128-x
58. Wright S, Dobranski MJ, Felkins KA, et al. Cytotoxic T-Lymphocyte Immunotherapy for Ovarian Cancer: A Pilot Study. J Immunotherapy. 2012; 35(2): 196-204. doi: 10.1097/CJI.0b013e318243f213
59. Robinson WR. Neoadjuvant Chemotherapy is rarely the Easy Way Out. J Clin Oncol. 2012; 30(13): 1563-4. doi: 10.1200/JCO.2011.40.8401
60. Alvarez RD, Gray HJ, Timmons, PF, Robinson WR, et al. We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality, and reimbursement policies. Gynecol Oncol. 2013; 129: 3-4. doi: 10.1016/j.ygyno.2013.02.010
61. Robinson WR, Cantillo E. Debulking Surgery and Intraperitoneal Chemotherapy are Associated with Decreased Morbidity in Women Receiving Neo-Adjuvant Chemotherapy for Ovarian Cancer. Int J Gynecol Cancer In Press. 2014; 24(1):43-47. doi: 10.1097/IGC.0000000000000009.
62. Robinson W. Gynecologic Cancer Research at a Crossroads. Gynecol Obstet Res Open J. 2014; 1(1): e1-e2. doi: 10.17140/GOROJ-1-e001